Preliminary results of a randomized multicenter controlled trial comparing interferon (IFN) thrice weekly in combination with ribavirin (RBV) with interferon daily in combination with ribavirin and amantadine (AMA) in the treatment of chronic hepatitis C in human immune deficiency virus (HIV) co-infected patients.

被引：0
|
作者：
Puoti, M
Zanini, B
Quinizan, P
Santantonio, T
Cavaliere, R
Roldan, EQ
Castelli, F
Suter, F
Pastore, G
Carosi, G
机构：
[1] Univ Brescia, AO Spedali Civili Brescia, MaSTer HIV HCV Coinfect Study Grp, Brescia, Italy
[2] Osped Riuniti Bergamo, Div Malattie Infett, I-24100 Bergamo, Italy
[3] Univ Bari, Clin Malattie Infett, Bari, Italy
来源：
HEPATOLOGY | 2002年 / 36卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1692
引用
收藏
页码：586A / 586A
页数：1
相关论文
共 50 条
  • [21] Retreatment for chronic hepatitis C of interferon non-responder patients.: Preliminary results of a multicenter randomized controlled trial of interferon plus ribavirin versus interferon alone.
    de Lédinghen, V
    Bernard, PH
    Trimoulet, P
    Bourlière, M
    Portal, I
    Rémy, AJ
    Szostak, N
    Longo, F
    Thiefin, G
    Abergel, A
    Dumas, F
    Lucidarme, D
    Blanc, P
    Zylberberg, H
    Capron, D
    Doll, J
    Fleury, H
    Couzigou, P
    HEPATOLOGY, 1998, 28 (04) : 374A - 374A
  • [22] Activity of combination therapy with interferon alfa-2b plus ribavirin in chronic hepatitis C patients co-infected with HIV
    Dieterich, DT
    Purow, JM
    Rajapaksa, R
    SEMINARS IN LIVER DISEASE, 1999, 19 : 87 - 94
  • [23] A randomized trial to assess the efficacy of interferon-alpha daily in combination with ribavirin in the treatment of naive patients with chronic hepatitis C
    Tassopoulos, NC
    Ketikoglou, I
    Tsantoulas, D
    Raptopoulou, M
    Hatzis, G
    Vafiadis, I
    Sidiropoulos, L
    Kanatakis, S
    Anagnostopoulos, G
    Sypsa, V
    Hatzakis, A
    JOURNAL OF VIRAL HEPATITIS, 2003, 10 (05) : 383 - 389
  • [24] Sustained virologic response (SVR) following interferon (IFN) and ribavirin (RBV) therapy for hepatitis C (HCV) patients who are co-infected with HIV
    Dieterich, DT
    Suciu, L
    Goldman, DJ
    Weisz, KB
    Jonea, J
    CLINICAL INFECTIOUS DISEASES, 2000, 31 (01) : 215 - 215
  • [25] Interferon α-2b/ribavirin combination therapy in HIV/HCV co-infected persons:: Results of a multicenter randomized, double-blind, controlled trial.
    Kostman, JR
    Smith, JJ
    Giffen, CA
    Frost, KR
    HEPATOLOGY, 2001, 34 (04) : 330A - 330A
  • [26] High interferon (IFN) daily doses in combination with ribavirin (RBV) are cost effective in the treatment of hepatitis C in HIV coinfected subjects without sustained response to interferon monotherapy.
    Puoti, M
    Zanini, B
    Quirizan, P
    Santantonio, T
    Scalise, G
    Ghinelli, F
    Chiodo, R
    Pastore, G
    Castelli, F
    HEPATOLOGY, 2002, 36 (04) : 586A - 586A
  • [27] Randomized controlled trial of combination therapy with interferon (IFN) ALFA-2A and ribavirin, in patients with chronic hepatitis C who relapsed after interferon therapy.
    Marcellin, P
    Hezode, C
    Castelnau, C
    Barange, K
    Couzigou, P
    Larrey, D
    Rosmorduc, O
    Tran, A
    Martinot, M
    Degott, C
    Saint-Marc girardin, MF
    HEPATOLOGY, 1999, 30 (04) : 192A - 192A
  • [28] Induction doses of interferon-α-2a in combination with ribavirin and/or amantadine for the treatment of chronic hepatitis C in non-responders to interferon monotherapy:: a randomized trial
    Salmeron, J.
    Diago, M.
    Andrade, R.
    Perez, R.
    Sola, R.
    Romero, M.
    de la Mata, M.
    Granados, R.
    Ruiz-Extremera, A.
    Munoz de Rueda, P.
    JOURNAL OF VIRAL HEPATITIS, 2007, 14 (02) : 89 - 95
  • [29] Interferon and ribavirin combination therapy for chronic hepatitis C in human immunodeficiency virus-infected patients with congenital coagulation disorders
    Sauleda, S
    Juárez, A
    Esteban, JI
    Altisent, C
    Ruiz, I
    Puig, L
    Esteban, R
    Guardia, J
    HEPATOLOGY, 2001, 34 (05) : 1035 - 1040
  • [30] Erythropoictic response to anemia is decreased in patients infected with hepatitis C virus (HCV) receiving combination ribavirin and pegylated interferon (RBV/PEG-IFN) therapy
    Balan, V
    Wu, GY
    Muir, AJ
    Keeffe, EB
    Bowers, PJ
    GASTROENTEROLOGY, 2003, 124 (04) : A751 - A751
12345